Where were you in 1978?
Silimed was already thinking about the well-being of his patients.
Present in the market since 1978, SILIMED is the largest manufacturer of silicone gel implants in Latin America, it is present in several countries and is the sales leader in the Brazilian market.
For more than 40 years it has contributed to plastic surgery, promoting research, scientific studies and the development of the best technologies, always in collaboration with Plastic Surgeons.
All Silimed products are made with top quality raw materials and state-of-the-art technology, which guarantees all the necessary certifications to operate in different countries.
Silimed plans a future of growth and world leadership in the different markets in which it operates, without losing its essence, by increasingly connecting science and wellness.
Activities started in Brazil by importing breast implants from France. Then, in 1981, it began manufacturing its own implants and the following year it began exporting to Argentina. The first 10 years were characterized by important challenges for a Brazilian industry that, in collaboration with the medical class, began to strengthen in its country and in Latin America.
In 1989 it developed its own innovative technology for the production of vulcanized polyurethane foam coated breast implants. That same year it expanded its market share and began exporting its products to Europe.
It was the first company in the world to identify its products with a unique serial number, guaranteeing control, traceability and security. This was followed by other manufacturers and required as a form of credibility for plastic surgeons, patients, and certification bodies.
After two decades of constant growth, it has established itself as a leader in the Brazilian market and as one of the main players worldwide.
To meet the high demand, it built a new factory in 2003, expanding its production capacity and bringing in new technological resources.
In this decade it has invested in two major product innovations. In 2006, it relaunched the breast implant with a conical design, an exclusive Silimed model to this day. In 2008, it launched a line of breast implants with an exclusive design concept to satisfy different biotypes, the Biodesign Collection, a complete matrix, with 5 formats and up to 4 projections for each base size.
The beginning of this decade was marked by the great achievement of being the first non-US implant manufacturer to receive FDA approval.
In the same decade, the group of young people who started this great company restructured Silimed's leadership and, without losing its essence and brand value, chose a family member, Gabriel Robert, to lead the company as CEO. A new, more dynamic and future-oriented management model is applied. This group is now part of the board of directors.
At the age of forty, a new cycle of challenges has begun, with the opening of international subsidiaries, the construction of a new factory and the search for technological innovations.